Quantitative regression of qFibrosis with resmetirom: Exploratory histologic endpoints from the MAESTRO-NASH phase III clinical trial

Journal:

Journal of Hepatology

Published:

2026-03-25

DOI:

10.1016/j.jhep.2026.03.021

Affiliations:

7

Authors:

11

Go to article

Institutions	Authors	Share
Madrigal Pharmaceuticals, United States of America (USA)	5.000000	0.45
Histoindex Pte Ltd., Singapore	3.000000	0.27
Duke University Health System, United States of America (USA)	1.000000	0.09
Saarland University Medical Center (UKS) / Faculty of Medicine, Saar-Uni, Germany	0.500000	0.05
Saarland University (Saar-Uni), Germany	0.500000	0.05
Liverpat, France	0.500000	0.05
Paris Cité University, France	0.500000	0.05

Interested in Clinical Sciences?